发明公开
EP2111865A1 UTILIZATION OF THE FUNCTION OF RARE SUGAR AS PROMOTER FOR THE MIGRATION OF GLUCOKINASE FROM NUCLEUS TO CYTOPLASM
审中-公开
稀有糖的功能的一种手段用来提高核葡糖激酶的迁移关闭进入细胞质
- 专利标题: UTILIZATION OF THE FUNCTION OF RARE SUGAR AS PROMOTER FOR THE MIGRATION OF GLUCOKINASE FROM NUCLEUS TO CYTOPLASM
- 专利标题(中): 稀有糖的功能的一种手段用来提高核葡糖激酶的迁移关闭进入细胞质
-
申请号: EP07739883.2申请日: 2007-03-27
-
公开(公告)号: EP2111865A1公开(公告)日: 2009-10-28
- 发明人: TOKUDA, Masaaki , IZUMORI, Ken , TOYODA, Yukiyasu , MIWA, Ichitomo
- 申请人: National University Corporation Kagawa University , Matsutani Chemical Industry Co., Ltd.
- 申请人地址: 1-1, Saiwai-cho Takamatsu-shi, Kagawa 760-8521 JP
- 专利权人: National University Corporation Kagawa University,Matsutani Chemical Industry Co., Ltd.
- 当前专利权人: National University Corporation Kagawa University,Matsutani Chemical Industry Co., Ltd.
- 当前专利权人地址: 1-1, Saiwai-cho Takamatsu-shi, Kagawa 760-8521 JP
- 代理机构: TBK-Patent
- 优先权: JP2006310982 20061117
- 国际公布: WO2008059625 20080522
- 主分类号: A61K31/7004
- IPC分类号: A61K31/7004 ; A23L1/30 ; A61P3/04 ; A61P3/06 ; A61P3/10 ; C07H3/02
摘要:
Screening for a glucokinase-activating substance among rare sugars and providing a composition for treating disordered conditions in association with glucokinase activity, the composition containing the glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm, the promoting agent containing D-psicose and/or D-tagatose as the active ingredient, or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions. The disordered conditions in association with glucokinase activity are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. The composition is in a pharmaceutical form, and contains D-psicose and/or D-tagatose together with one or more pharmaceutically acceptable carriers.
公开/授权文献
信息查询